New Alzheimer’s disease treatments for presymptomatic patients will increase the AD market size in the years ahead; the multiple sclerosis segment is undergoing a strong growth phase based on the arrival of promising molecules with disease-modifying characteristics and novel mechanisms of action.
A new wave of innovation, productivity, and growth is helping Novartis move past significant patent expirations into the next phase of growth for the company.
J&J emerged from a transitional 2012 continuing to generate annual sales increases and make significant advances on multiple fronts; the company is building out strategic platforms and establishing new ones.
GlaxoSmithKline continues to follow through on management’s three strategic priorities in order to increase growth, reduce risk, and improve the company’s long-term financial performance.
Amgen is concentrating on the product pipeline, international expansion, and its entry into the biosimilar market to drive company growth during the years ahead.
Johnson & Johnson, Amgen, and Allergan headline the category winners for 2013.
Amgen ended 2011 with good momentum that carried over into 2012, as revenue is on pace to increase by a double-digit percentage year over year; various acquisitions are helping build the biotechnology entity’s global footprint and R&D program.
After generating company-record sales in 2011, to help offset the patent-protection loss of its top-selling product, Novartis is capitalizing on growth from other billion-dollar brands and the Alcon business while awaiting a new generation of drug and vaccine blockbusters.
The world’s largest and most diverse maker of healthcare products is seeking to improve manufacturing problems and capitalize on new drugs and indications; the Synthes acquisition is providing positive effects.
GlaxoSmithKline management is focused on growing a diversified global business, delivering products of value, and simplifying the company’s operating model.